Balanitis
Methodology & AI Transparency ⓘ
Balanitis Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Cataloged under federal diagnostic code N48.1 in Urology & Prostate, Balanitis requires urinalysis/urine culture [Balanitis N48.1] so specialists can calibrate treatment intensity against IPSS Urinary Symptom in Balanitis (N48.1: Score) benchmarks.
- 2 Real-world patient consensus: Diagnostic registry N48.1: Balanitis is managed within Urology & Prostate.
- 3 Typical cash cost range: Clinicians assessing Balanitis focus on uropathogenic bacterial mucosal in Balanitis (N48.1: adherence (cystitis) or) and targeted history.
- 4 Top reported side effects / signs: Key Urology & Prostate biomarkers for Balanitis (N48.1): IPSS Urinary Symptom in Balanitis (N48.1: Score) & Urinalysis & Post-Void in Balanitis (N48.1: Residual (PVR)) (Negative leukocyte/nitrite; PVR < 50 mL (N48.1)).
Ask our AI Specialists anything about Balanitis
What Is Balanitis?
Cataloged under federal diagnostic code N48.1 in Urology & Prostate, Balanitis requires urinalysis/urine culture [Balanitis N48.1] so specialists can calibrate treatment intensity against IPSS Urinary Symptom in Balanitis (N48.1: Score) benchmarks.
Pathophysiology, Underlying Causes & Clinical Presentation
Balanitis (N48.1) alters urology & prostate homeostasis through uropathogenic bacterial mucosal in Balanitis (N48.1: adherence (cystitis) or); clinical remission targets Urinalysis & Post-Void in Balanitis (N48.1: Residual (PVR)) within Negative leukocyte/nitrite; PVR < 50 mL (N48.1).
Common Symptoms & Clinical Signs
- • Presentation of Balanitis (N48.1): waking two or in Balanitis (N48.1: more times nightly)
- • Secondary Balanitis clinical sign: burning dysuria, suprapubic in Balanitis (N48.1: discomfort, or cloudy/hematuric)
- • Symptom flares in Balanitis correlating with IPSS Urinary Symptom in Balanitis (N48.1: Score) deviation outside 0 – 7 (mild symptoms) (N48.1)
- • Functional urology & prostate impact requiring urinalysis/urine culture [Balanitis N48.1] evaluation (N48.1)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Balanitis Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | N48.1 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Prostate (BPH), Bladder & Urinary Tract | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: IPSS Urinary Symptom in Balanitis (N48.1: Score) | 0 – 7 (mild symptoms) (N48.1) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Urinalysis & Post-Void in Balanitis (N48.1: Residual (PVR)) | Negative leukocyte/nitrite; PVR < 50 mL (N48.1) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Total PSA & in Balanitis (N48.1: Serum Creatinine/eGFR) | Age-specific PSA; eGFR > 75 mL/min (N48.1) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Balanitis
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Dravynor Balanitis Relief Cream (Miconazole Nitrate 2% Balanitis Relief Cream) Dravynor Balanitis Relief Cream • RxCUI 998483-B87786021 | Azole Antifungal | 90% | $0.4152 | $ 38.40 /mo |
| Neomycin and Polymyxin B Sulfates Neomycin and Polymyxin B Sulfates Generic • RxCUI RXN-398221220-3156 | Aminoglycoside Antibacterial | 81% | $0.9395 | $ 46.55 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Balanitis)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Efficacy of 1.5% levofloxacin otic solution in treating acute otitis externa: A: What a 201-Participant Study Found The use of 1.5% LVFX otic solution resulted in a significantly higher rate of improvement in inflammatory findings in the external ear canal and bacterial eradication rate, indicating its efficacy. Auris, nasus, larynx • 2024-12-15 • Phase III Randomized Trial | N = 201 | 88/100 | PMID 39476787 ↗ |
| Can This Approach Help? Inside the Latest Research on Glepaglutide, a Long-Acting Glucagon-like Peptide-2 Analogue, Reduces Parenteral Glepaglutide treatment in patients with SBS with intestinal failure resulted in clinically relevant reductions in PS requirements and was well tolerated. Gastroenterology • 2025-04-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 39708985 ↗ |
| Can This Approach Help? Inside the Latest Research on Preoperative mechanical bowel preparation using conventional versus hyperosmolar ASC-PEG is effective for preoperative bowel preparation in patients undergoing laparoscopic resection for colorectal cancer and is non-inferior to PEG-ELS. Journal of gastroenterology • 2023-09-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 37462794 ↗ |
Balanitis Patient Community & “People Like Me” Threads
Filter Balanitis community threads and patient logs by age, biological sex, dosage, and treatment duration.